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a b s t r a c t
This study characterized the extent and patterns of self-reported drug use among aging adults with
and without HIV, assessed differences in patterns by HIV status, and examined pattern correlates. Data
derived from 6351 HIV-infected and uninfected adults enrolled in an eight-site matched cohort, the
Veterans Aging Cohort Study (VACS). Using clinical variables from electronic medical records and socio-
demographics, drug use consequences, and frequency of drug use from baseline surveys, we performed
latent class analyses (LCA) stratified byHIV status and adjusted for clinical and socio-demographic covari-
ates. Participants were, on average, age 50 (range 22–86), primarily male (95%) and African-American
(64%). Five distinct patterns emerged: non-users, past primarily marijuana users, past multidrug users,
current high consequence multidrug users, and current low consequence primarily marijuana users.
HIV status strongly influenced class membership. Non-users were most prevalent among HIV uninfected
(36.4%) and current high consequence multidrug users (25.5%) were most prevalent among HIV-infected.
While problems of obesity marked those not currently using drugs, current users experienced higher
prevalences of medical or mental health disorders. Multimorbidity was highest among past and cur-
rent multidrug users. HIV-infected participants were more likely than HIV-uninfected participants to be
current low consequence primarily marijuana users. In this sample, active drug use and abuse were com-
mon. HIV-infected and uninfected Veterans differed on extent and patterns of drug use and on important
characteristicswithin identified classes. Findings have the potential to inform screening and intervention
efforts in aging drug users with and without HIV.
© 2010 Elsevier Ireland Ltd. All rights reserved.
 A summary table of the results is available with the online version of this article.
Please see Appendix A at doi:10.1016/j.drugalcdep.2010.02.020.
 Disclaimer: The views expressed in this article are those of the authors and do
not necessarily reflect the position or policy of the Department of Veterans Affairs.
∗ Corresponding author at: 111 Plain St. Building, Rm 111, Providence, RI 02903,
USA. Tel.: +1 401 444 3845; fax: +1 401 444 5040.
E-mail address: traci.c.green@brown.edu (T.C. Green).
1. Introduction
Drug use among older adults in the US is occurring at unprece-
dented high levels and growing. The baby boom generation (i.e.,
people born 1946–1964) has higher prevalences of lifetime drug
use compared to all previous generations and appears to be con-
tinuing their drug use later into life (Han et al., 2009a). In 2007, all
adults aged 50–59 were baby boomers; recent national data reveal
that in the sameyear the prevalence of self-reported past year illicit
drug use in this age group nearly doubled from 2002 figures (Han
0376-8716/$ – see front matter © 2010 Elsevier Ireland Ltd. All rights reserved.
doi:10.1016/j.drugalcdep.2010.02.020
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et al., 2009b). Updated projections forecast that by 2020, the num-
ber of adults 50 or older with substance use disorder will more
than double from 2.8 million in 2002–2006 to 5.7 million (Han
et al., 2009b), a projection 30% higher than previously estimated
(Colliver et al., 2006; Gfroerer et al., 2003). The enormity of this
problem is compounded by under-recognition of substance use in
older people (Levin and Kruger, 2002), limited data on the types
and patterns of their drug use (Levy, 1998; Lieberman, 2000), the
lack of substance abuse treatment services for older adults (Office
of Applied Studies, 2007), under-utilization of screening tools for
primary care practitioners to identify substance abuse problems
(Friedmann et al., 2001; Kim et al., 2007; Lewis, 1997), and the
medical andpsychological comorbidities that often accompanyand
complicate the health status of older drug users (Geriatric Mental
Health Foundation, 2010; Reid and Anderson, 1997; Reid et al.,
2002; Simoni-Wastila and Yang, 2006).
At the same time, HIV is increasingly affecting older popu-
lations because HIV-infected persons are living longer on more
effective treatments while HIV incidence in this age group is on
the rise. Approximately 10% of new HIV infections in the US occur
among people over 50 years of age (Centers for Disease Control
and Prevention, 2008). Drug use, especially by injection, is one of
the primary modes of HIV and hepatitis transmission, and thus one
might expect HIV-infected older adults to have higher prevalences
of injection drug use (IDU) compared to their uninfected peers. On
the other hand, HIV incidence among IDUs has declined by 50% or
greater over the past 20 years (Des Jarlais et al., 2000; Lee et al.,
2003), and, in many places, HIV transmission among IDUs has been
associated with sexual transmission rather than unsafe injection
(Centers for Disease Control and Prevention, 2009; Kral et al., 2001;
Strathdee et al., 2001). Furthermore, most illicit drug use in the
US is non-injection (Substance Abuse and Mental Health Services
Administration, 2009). Regardless of HIV status and transmission
category, patterns of current drug use are poorly understood in
older adults (Rabkin et al., 2004; Rosenberg, 1995; Schlaerth, 2007).
The nexus of these three issues – drug use, HIV, and aging – is
an understudied yet looming problem. Evidence suggests that HIV
may speed aging and exacerbate problems of older age. Active drug
use contributes to poor health outcomes for people with and with-
out HIV alike (AETC, 2006; Bruce et al., 2008; Kapadia et al., 2005),
and may be particularly harmful if addictive disorders persist later
in life. Older adults with HIV may thus be disproportionately bur-
denedby thenegativeconsequencesofongoingdrugabuse (Zanjani
et al., 2007). For example, both older age and HIV infection are
risk factors for unintentional fatal drug overdose (Darke and Zador,
1996; Tardiff et al., 1997;Wang et al., 2005). Biologicalmechanisms
of this elevated riskmay be due to changes inmetabolism and body
water content in older adults that can lead to higher serum drug
concentrations over prolonged periods, thereby increasing risks of
unintentional injuries such as drug overdose.
Few studies have been conducted with sufficient power to
contrast drug use by HIV status and age; even fewer provide gener-
alizable data (Levy, 1998; Lieberman, 2000) or detailed information
regarding medical and psychiatric comorbidities related to sub-
stance use problems. One study, limited by sample size, found that
lifetime drug dependence was higher for the HIV-infected than
uninfected individuals, and that expected age-associated declines
in diagnoses of dependence were not detected among the HIV-
infected (Rabkin et al., 2004). Analysis of data from a larger, more
diverse sample is needed to assist clinicians and policy makers in
developing evidence-based responses to changing patterns of drug
use in aging populations.
In thispaper,weuseddata fromtheVeteransAgingCohort Study
(VACS) (Justice et al., 2006a), a longitudinal, prospectively con-
sented, observational cohort study conducted among HIV-infected
Veterans and age-, race- and site-matched HIV uninfected controls
receiving medical care at one of eight US Veterans Administra-
tion (VA) facilities to: (1) characterize patterns of self-reported
drug use in a large and diverse cohort of aging HIV-infected and
uninfected US Veterans and analyze their construct validity; (2)
assess pattern differences by HIV status; and (3) describe demo-
graphic, medical and psychiatric pattern correlates within this
population. To accomplish these aims, we employed latent class
analysis (LCA) (Agrawal et al., 2007; Lubke and Muthen, 2005;
Muthen, 2006) to identify patterns of behavior, using all available
baseline VACS information. We chose this empirical approach to
minimize the potential for measurement error, bias, or oversimpli-
fication (Kapadia et al., 2005) inherent when a priori definitions are
used to aggregate and categorize complex behaviors.
2. Methods
2.1. Sample
VACS has been described extensively elsewhere (Conigliaro et
al., 2004; Justice, 2006; Justice et al., 2006a,b, 2001); design and
population characteristics pertinent to this analysis are reported
here. Initiated in 2002, the eight-site VACS aimed to explore comor-
bidities and behaviors affecting medical outcomes in the broader
context of aging and HIV (Justice et al., 2006a, 2001). HIV-infected
participants were recruited from VA infectious disease clinics;
uninfected participants were recruited from VA general medicine
clinics. Participants are largely male, representative of the VA pop-
ulation in care for HIV (Justice et al., 2006a). VACS is characterized
by anetwork of administrative, clinical, and research resources that
allows linkage of annual self-reported survey data to electronic
medical records (EMR), vital statistics, pharmacy prescriptions, and
healthcare use. Annual loss to follow up is <5%.
2.2. Measures
2.2.1. Drug use and consequences. The VACS baseline survey
included items on frequency of use (Centers for Disease Control
and Prevention, 2002) of marijuana, heroin/opioids, cocaine/crack,
and stimulants (amphetamines, speed, crystalmethamphetamine).
Responses for marijuana and stimulant/cocaine use were: never,
no use in the past year, some use in the past year (monthly or
less often), and heavy use in the past year (weekly to daily use).
For heroin/opioids the response options were never, not in the
past year, any past year use. Due to sparseness of data and lack
of clinically meaningful differences in their use, stimulant use was
grouped with cocaine/crack use. The degree of consequence (high,
low) experienced due to drug use was derived from an item within
the Michigan Composite International Diagnostic Interview (CIDI-
SF) (Kessler et al., 1998): “In the past 12 months, did your use of
drugs ever interferewith yourwork at school, or a job, or at home?”
Responseswereneverdruguse, usemore than1year ago (problems
may or may not have been experienced), no problems experienced
in the past year, or problems experienced in the past year. Together,
these items comprised the indicators for the LCA.
2.2.2. Covariates. Variables known to be associated with drug use
thatmight differentiate the patterns included socio-demographics,
comorbidities (hepatitis C (HCV), medical and psychiatric condi-
tions) (Kilbourneet al., 2001), historyof andpast year injectiondrug
use, and past year receipt of VA substance abuse and mental health
treatment. The selection of candidate covariates of the LCA was
a theoretically driven one that was tested statistically in the LCA.
The theoreticalmodel informing our analyseswasGelberg’s Behav-
ioral Model for Vulnerable Populations, which amends Andersen’s
Behavioral Model to explicitly include domains especially rele-
vant to vulnerable populations (e.g., the homeless) to explain and
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predict personal health practices (Gelberg et al., 2000). In this
model, health outcomes and behaviors are functions of predispos-
ing factors, enabling resources, and need. Predisposing domains
traditionally include demographics like age, gender, and ethnicity,
but were expanded to include vulnerable domains such as lifestyle
instability. In this analysis, we considered HIV positive Veterans as
a vulnerable population. Substance abuse, race/ethnicity, and gen-
der are conceptualized as predisposing factors; enabling resources
include having a regular care provider, HAART, and income; need
encompasses health status, presence of depressive symptoms, and
comorbidities; health behaviors act as intermediate outcomes and
include adherence to medication; and outcomes are disease pro-
gression and death. The focus of the present analysis is on the
interplay of predisposing, enabling, and need factors as covari-
ates of the LCA; the remaining domains are the subject of future
analyses. Socio-demographics included age, race/ethnicity, edu-
cation level, income, marital status, smoking, body mass index
((BMI) calculated based on self-reported height and weight) and
having ever been homeless or marginally housed. Current prob-
lem drinking was assessed by the AUDIT-C (Bush et al., 1998).
Other covariates included lifestyle instability (Gordon et al., 2006;
Kim et al., 2006; McFarland et al., 2003; Shapiro et al., 1999;
Song et al., 2000), approximated by past month homelessness and
concern about food availability, and quality of life (mental, physi-
cal composite scores) which was captured by the Short Form-12
(SF-12) (Ware et al., 1996). Comorbidities were identified using
International Classification of Diseases, 9th revision (ICD-9-CM)
codes from the participant’s EMR, grouped into clusters of medical
and psychiatric disease diagnoses, as previously reported (Goulet
et al., 2005, 2007). For participants with HIV, concurrent AIDS-
associated illness occurring 1 year before and 6 months after
baseline was defined according to the Centers for Disease Control
and Prevention’s (1993) case definition.
2.3. Analysis
2.3.1. Overview. We used LCA, a statistical method for creating
meaningful subgroups, or latent classes, based on similarities in
responses to a set of observed indicators. It is assumed that the
observed variables are independent from one another once con-
ditioned on the latent variable, an assumption known as local
independence (Hagenaars and McCutcheon, 2002). LCA produces:
(a) the prevalence of each latent class (i.e., prior probability that a
randomly chosen person will be in each class) and (b) the probabil-
ity of response to an indicator, conditional on the latent class. Class
categorizations arebasedon theprevalenceof the latent classes and
are mutually exclusive and exhaustive. While an individual has a
probability of membership in all of the latent classes, theoretically,
they belong to one true class. Based on the profile of the response
indicators, a putative name for the class can be derived. LCA has
a number of advantages. It can incorporate covariates that may
influence class membership (Muthen, 2004). LCA has been used
previously in evaluations of subjects with substance use disorders
(e.g., Monga et al., 2007). Also, LCA employs a full informationmax-
imum likelihood approach that allows for analysis of all available
data, assuming data aremissing at random. Thereforewewere able
to model using all available baseline cases instead of deleting those
with missing drug use data.
2.3.2. Modeling approach. First, we constructed a LCA model using
the entire sample (regardless of HIV status). We systematically
built from simple unadjusted to more complex adjusted models.
Unadjusted models considered one to seven classes. To identify
the optimal number of latent classes and the best fitting model,
we sought to minimize the Bayesian Information Criteria (BIC),
maximize entropy, a summary measure that conveys classification
quality (Muthen and Muthen, 2007), and yield interpretable latent
classes of >1% prevalence. Once a final model was selected, we
tested for differences by HIV status and then incorporated covari-
ates in an adjusted LCA model. Results describe the empirically
derived classes and their construct validity. Mplus version 5.1 soft-
ware (Muthen and Muthen, 2007) was used to fit LCA models.
2.3.3. Construct validity. Adjusted latent classes were compared
to other classifications of drug abuse and dependence obtainable
throughmedical records andVACS surveys. These included, respec-
tively, ICD-9-CM diagnoses and CIDI-SF score ≥4, indicating high
probability of fulfilling DSM-IV drug dependence criteria (Kessler
et al., 1998; Robins et al., 1988). A search of the participant’s EMR
1 year prior and 6 months after the survey visit date was con-
ducted of VA administrative records at the Austin Automation
Center (Austin, TX) for ICD-9-CM diagnosis codes 291.00–292.99
and 303.00–305.99 (Druss and Rosenheck, 2000). Patients were
coded dichotomously according to whether or not their EMR noted
abuse and/or dependence of alcohol or drugs. Using 2 and Kappa
statistics, we assessed how these related indicators mapped onto
the derived latent classes (Orlando et al., 2004, 2005; Tucker et al.,
2006) as “validating indicators”.
2.3.4. Differences by HIV status. By including HIV status as a covari-
ate that could have class-varying probabilities and comparing the
fit of nested models (Muthen and Muthen, 2007) using 2 tests
we assessed for differences by HIV status. Direct effects (i.e., HIV
effects drug use indicators directly versus through the latent class)
were tested in similar fashion. Based on these results, subsequent
LCA analyses were stratified by HIV status, to characterize disease-
specific class differences and correlates.
2.3.5. Adjusting for covariates. To examine correlates of classmem-
bership, we conducted latent class regression. We adjusted for
covariates by employing a steppedmodeling approach (Delucchi et
al., 2004). First, taking the modal predicted most likely class from
the unadjusted LCA as the outcome, class-specific differences were
tested for all covariates using bivariate analyses (Wald 2 tests for
categorical variables, ANOVAs or Kruskall–Wallace test for contin-
uous variables), stratified by HIV status. Due to the large number of
comparisons made, the overall ˛ level was Bonferroni-corrected
to p< .0013 (˛= .05/39). Variables found to be significant were
then entered into a multinomial logistic regression of the modal
predicted most likely class to determine factors independently
associated with membership (Ghandour et al., 2008). The resulting
significant covariates were considered candidates for the adjusted
latent class regression model. Then, HIV-specific LCAs were re-
estimated incorporating the candidate variables and checking that
covariates excluded earlier in the analysis did not significantly
improve fit, reduce variance, ormeasurably (≥10%) alter parameter
estimates. Last, by testing nested models, any candidate variables
that did not help differentiate classes were dropped from the final
adjusted latent class regression models. Results present the class-
and HIV-specific socio-demographic and health status variables.
This study was approved by institutional review boards at the Yale
School of Medicine and the VA Connecticut Healthcare System,
West Haven.
3. Results
3.1. Study sample
Participants were, on average, age 50 (range 22–86), primar-
ily male and African–American (Table 1). HIV-infected participants
were significantly more likely to be African–American, HCV
seropositive, not married or living with a partner, and to have
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Table 1
Characteristics of the HIV-infected (n=3160) and HIV uninfected (n=3191) VACS participants.
HIV− HIV+ p-value
N % N %
Age, mean (SD) 3191 50.7 (10.0) 3160 49.4 (8.8) <.0001
Vietnam era cohort† 2016 63.2 1881 59.5 .003
Male 2938 92.1 3080 97.5 <.0001
Race White 782 24.5 637 20.2 0.002
African–American 1974 61.9 2103 66.5
Hispanic 320 10.0 297 9.4
Other 115 3.6 123 3.9
Education < high school 1294 41.0 1276 40.7 .79
Ever homeless 1337 41.9 1515 47.9 <.0001
Homelessness, past month 380 11.9 256 8.1 <.0001
Married/living with partner 1240 39.1 711 22.8 <.0001
Annual income >$25,000 1046 32.8 747 23.6 <.0001
BMI categories Obese 1242 39.2 407 13.0 <.0001
Overweight 1186 37.4 1146 36.6 0.49
Normal 702 22.1 1457 46.5 <.0001
Underweight 39 1.2 123 3.9 <.0001
Smokes currently 1394 44.1 1656 52.6 <.0001
Mean (SD) SF-12 composite score Mental 3169 47.5 (11.8) 3149 46.7 (11.2) 0.004
Physical 3181 42.2 (11.4) 3148 43.5 (10.6) <.0001
HCV+ 767 24.0 1474 46.6 <.0001
Medical disease cluster 2236 70.1 1879 59.5 <.0001
Diabetes 730 22.9 402 12.7 <.0001
Hypertension 1705 53.4 944 29.9 <.0001
Renal disease 90 2.8 120 3.8 .003
Pulmonary disease 365 11.4 285 9.0 .001
Liver disease (not including hepatitis) 29 0.9 59 1.9 .001
Vascular disease 473 14.8 252 8.0 <.0001
Psychiatric disease cluster 880 27.6 738 23.3 <.0001
Schizophrenia 210 6.6 134 4.2 <.0001
Major depression, bipolar 569 17.8 539 17.1 .41
Post traumatic stress disorder 407 12.7 247 7.8 <.0001
Medical & psychiatric disease cluster‡ 655 20.5 530 16.8 <.0001
Past year treatment Substance abuse 536 16.8 449 14.2 0.004
Methadone maintenance 159 5.0 144 4.6 0.41
Mental health 1166 36.5 926 29.3 <.0001
IVD past year 137 4.3 231 7.4 <.0001
Alcohol use past year 2031 67.4 2048 68.4 0.39
AUDIT-C score (mean, SD) 3084 2.7 (2.9) 3026 2.6 (2.6) 0.014
Problem drinking cutoff+ 995 31.2 911 28.8 0.041
ICD-9 baseline diagnosis*: Alcohol abuse/dependence 740 23.2 586 18.5 <.0001
Drug abuse/dependence 799 25.0 793 25.1 0.96
CIDI-SF defined drug dependent* 409 13.5 449 14.9 0.14
AIDS-associated illnesses, past year – – 707 22.4 NA
AUDIT-C = alcohol use disorders identification test-consumption, BMI = body mass index, ICD-9 = International Classification of Diseases, 9th revision, CIDI-SF = Michigan
composite international diagnostic interview, short form, SD = standard deviation, IVD = intravenous drug use, HCV = hepatitis C virus, NA = not applicable.
* Variables used in validation of derived latent classes.
† Defined as born on or before December 31, 1955 (i.e., aged 18 or older at the last draft in 1973).
‡ Has at least one ICD-9-CM diagnosis within each of the medical and psychiatric disease clusters (i.e., multimorbidity).
+ Defined as >4 on AUDIT-C score.
past and recent histories of homelessness. Alcohol use was
similarly high across HIV status. Drug use was reported by
HIV-infected and uninfected participants, with a significantly
higher prevalence (p< .0001 for all indicators) among the former.
Self-reported drug use was higher than that captured by ICD-
9 diagnoses (Fig. 1) and other drug abuse/dependence criteria
(Table 1).
3.2. Latent classes based on drug use indicators: overall
For the full sample (N=6351), a five class unadjustedmodel pro-
vided the best fit to the observed data (entropy 5 class =0.94, BIC
5 class =39472.3 versus BIC 4 class =40126.5) and defined clini-
cally interpretable and relevant subgroups labeled for convenience
based on their profiles of response to the latent class indica-
tors as non-users, past primarily marijuana users, past multidrug
users, current high consequence multidrug users, and current low
consequence primarily marijuana users. Local independence was
checked by looking at bivariate residuals conditional on classmem-
bership associated with each pair of drug use indicators. p-Values
associated with these tests remained below critical values for
the stratified HIV positive model and two violations were found
with critical values flagging a significant dependence in the HIV
negative model. To account for these few large residuals, direct
effects were tested between the indicators (cocaine/stimulate use,
heroin/opiate use and drug use consequences). Inclusion of the
direct effects did not further improve model fit or significantly
change the estimated model parameters or probabilities so they
werenot retained in thefinalmodels.HIVstatus strongly influenced
class membership, evidenced by significantly improved model fit
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Fig. 1. Latent class indicators of drug use among HIV-infected and uninfected VACS participants (n=6351)*.
Those who indicated ‘not past year use’ for problematic drug use may or may not have experienced problems in the past with their drug use.
(2 difference =279.56, degrees of freedom=4, p< .0001). HIV sta-
tus significantly (p< .001) differentiated 18 of the 20 possible class
membership combinations (five comparisons, k-1 classes). Com-
pared to non-users (reference group), HIV-infected subjects were
more likely to be classified as past multidrug users (OR 2.3), cur-
rent multidrug users (OR 2.4) or, most likely, as current primarily
marijuana users (OR 3.3, all p< .0001).
3.3. HIV-specific LCAs
Based on these strong HIV effects, we conducted unadjusted
LCAs stratified by HIV status, and found that the 5 class model
again fit best (HIV-infected: BIC 5 class =21215.3 versus BIC 4
class =21463.2; HIV uninfected: BIC 5 class =21215.3 versus BIC
4 class =21463.2). When the resultant classes were treated as
outcomes in bivariate and multivariable analyses, 19 candidate
covariates were identified for consideration in adjusted LCA
models. In fitting the multinomial regressions, we detected non-
linearity in effects for age, anticipated from known relationships
between aging and drug use and possible generational effects
(Rosenberg, 1995; Schlaerth, 2007). At age 60, probability of mem-
bership in a current drug use class was 0.19 for the HIV-infected
and 0.087 for the HIV-infected; at age 70 these probabilities were
0.066 and 0.032, respectively.
In the final latent class regression modeling step, adjusting
the LCA models retained the underlying structures of the unad-
justed models, improved model fit, and maintained high entropy
(HIV-infected: entropy= .92, BIC 5 class =17035.4; HIV uninfected:
entropy=0.93, BIC 5 class =15258.5). While the item-response
probabilityprofileswere similar byHIV status for thenon-users and
past multidrug user classes, they differed by HIV status for past pri-
marilymarijuanaandall currentuser classes (Table2). Compared to
the HIV uninfected, the probability of reporting high consequence
drug use was lower for the HIV-infected current multidrug users
(0.64 HIV+ versus 0.74 HIV−). For the low consequence primar-
ily marijuana use class, HIV-infected participants were more likely
to have a history of cocaine/stimulant use (0.43 HIV+ versus 0.32
HIV−) whereas the HIV uninfected were more likely non-users of
cocaine/stimulants (0.47 HIV− versus 0.35 HIV+).
3.4. Construct validity
3.4.1. Agreement of LCA classes and clinical diagnoses. For both HIV-
infected and uninfected, Kappa statistics were moderately high
between the high consequence multidrug users and drug depen-
dence according to CIDI (K=0.55 HIV+, K=0.68 HIV−) and ICD-9
(K=0.45 HIV+, K=0.59 HIV−). Lower bounds of the Kappa statis-
tics for all measures of agreement lay above the suggested 0.40
minimum (Landis and Koch, 1977; Sim and Wright, 2005). The
remaining classes had small and negative Kappas with the two
drug dependence criteria. Regardless of HIV status, the non-user
class had the most negative Kappas (range: −0.32 to −0.18) with
the drug dependence criteria. Negative Kappas mean agreement
occurred less often than predicted by chance, suggesting genuine
disagreement (Juurlink and Detsky, 2005), which is expected in the
non-use and low drug use categories. Most members of the current
multidrug users class exhibited abuse/dependence criteria, regard-
less of HIV status, though this was consistently lower among the
HIV-infected. In sum, results suggest construct validity of the latent
classes was achieved.
3.5. Class descriptions
Table 3 displays socio-demographic and health status charac-
teristics of the adjusted drug classes by HIV status. Hispanic/other
ethnicity, sex (HIV-infected) and education level (HIV uninfected)
were not different across classes. Health status variables not statis-
tically significant across class were BMI categories for overweight
and underweight, renal disease, pulmonary disease, and, for the
HIV uninfected, the medical disease cluster. For HIV-infected par-
ticipants, vascular disease prevalence did not differ by class. All
other variables reportedwere statistically significant across classes
by Wald tests using a Bonferroni-adjusted p-value of 0.0013. Class
descriptions below summarize findings reported in Tables 2–4 but
focus on drug use and health status results only, in the interest of
space.
3.5.1. Class 1: non-users (VACS prevalence: 36.4% HIV−, 19.6% HIV+).
Measures of mental quality of life were generally high for non-
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users, while for the HIV uninfected, the median physical composite
score suggested a lower quality of life. Obesity in this class was
the second highest at 15.7% of the HIV-infected and 42.0% of the
HIV uninfected. Past year alcohol use was common but AUDIT-C
scores were low and, as expected, non-users had a low prevalence
of substance abuse ormental health treatment. Non-users had high
prevalences of chronic medical disease (i.e., diabetes, hypertension
and vascular disease) and the lowest prevalence of psychiatric dis-
eases of all classes. HCV was relatively low for HIV-infected and
uninfected non-users. Compared to all other classes, HIV-infected
subjects in this class experienced the fewest AIDS-associated ill-
nesses.
3.5.2. Class 2: past primarilymarijuana users (VACS prevalence: 14.5%
HIV−, 15.8% HIV+). The prevalence of this class was similar by HIV
status. Past primarily marijuana users shared similar characteris-
tics with the non-user class, regardless of HIV status. Differences
were primarily socio-demographic (more non-minorities, higher
educational status among HIV+; highest income and employment).
Additionally, past primarily marijuana users more often reported
morepast year alcoholusealthough theirAUDIT-C scoreswere sim-
ilar to those of non-users.Medical but not psychiatric diseaseswere
less prevalent than in non-users. The HIV-infected had a higher
prevalence of AIDS-associated illnesses than in non-users but this
prevalencewas lowrelative to other classeswithdrugusehistories.
3.5.3. Class 3: past multidrug users (VACS prevalence: 19.1% HIV−,
20.1% HIV+). Overall prevalence of this class was similar by HIV
status, but the populations reported different health and drug use
experiences. A history of injection drug use was common among
the past multidrug users, more so among the HIV-infected. Past
multidrug users had the lowest reported alcohol use of all classes
but there were higher AUDIT-C scores among those continuing to
drink. This class also reported more recent treatment for substance
abuse andmental health problems than classes 1, 2 and 5. Pastmul-
tidrug users suffered from significant health problems, reflected in
low SF-12 physical and mental scores. The highest prevalences of
obesity and medical diseases were found in this class. Among the
HIV-infected, chronicmedical diseases (i.e., diabetes, hypertension,
vascular disease) and HCV peaked in this class.
3.5.4. Class 4: high consequence, multidrug users (VACS prevalence:
18.0% HIV−, 25.5% HIV+). History of and current drug injection
distinguished this class, with current injection more common
among the HIV-infected. Evidence suggested that some mem-
bers of this class transitioned from injecting to non-injecting drug
use (42.3% ever to 19.8% past year HIV−, 57.9% ever to 27.1%
past year HIV+), though available data cannot discern when such
changes took place. Continued drug use was primarily through
smoking marijuana and non-injection use of heroin/opioids and
cocaine (including crack). Class members also reported current
problemdrinking. History of recent substance abuse treatment and
methadone treatment was greater in this than for all other classes
and they reported poor quality of life scores. Prevalence of obesity
was low as were medical diseases associated with obesity, espe-
cially diabetes, hypertension, and vascular disease (HIV− only). On
the other hand, prevalence of HCV and psychiatric diagnoses—in
particular, major depression and bipolar—was high. Co-occurrence
of medical and psychiatric disease (i.e., multimorbidity) and AIDS-
associated illness was highest in this class.
3.5.5. Class 5: low consequence, primarily marijuana (VACS preva-
lence: 12.0% HIV−, 19.0% HIV+). The distinct differences by disease
status in this class were notable. Among the HIV-infected in this
class, socio-demographics (e.g., non-minority, educational status,
income, and stability) and low AUDIT-C scores were similar to
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Table 3
Characteristics of each of the five covariate-adjusted latent classes by HIV status.
Non-users Past primarily marijuana Past multidrug Highconsequence,multidrug Low consequence,
primarily marijuana
Class 1 Class 2 Class 3 Class 4 Class 5
HIV− HIV+ HIV− HIV+ HIV− HIV+ HIV− HIV+ HIV− HIV+
Class prevalence (%) 36.4 19.6 14.5 15.8 19.1 20.1 18.0 25.5 12.0 19.0
Age <40 15.0 20.6 20.6 17.6 4.6 3.3 8.0 7.3 14.6 18.5
41–50 25.8 30.4 31.3 35.2 44.9 43.2 58.2 51.1 33.7 40.6
51–60 33.5 28.0 35.8 35.7 44.3 46.9 31.3 37.3 40.3 34.5
>60 25.7 21.0 12.3 11.5 6.2 6.6 2.5 4.3 11.4 6.4
Vietnam era cohort+ 69.6 57.3 58.1 56.6 68.1 70.8 50.1 57.8 62.3 53.2
Female‡ 11.7 2.6 9.2 2.1 6.6 2.4 2.5 2.8 4.7 2.3
Race African American 54.5 64.6 56.2 54.5 63.0 66.6 79.6 80.4 56.4 53.0
Hispanic/other†‡ 14.2 12.3 15.0 11.7 15.0 16.0 9.1 10.4 13.7 15.4
Married/living with partner 47.2 24.4 45.0 23.2 36.8 25.5 21.6 13.9 39.8 28.8
Education < high school† 38.8 35.7 37.8 33.9 38.6 42.8 46.0 49.9 42.4 31.6
Income >$25,000 42.8 31.0 45.3 34.3 28.0 20.7 13.0 10.9 31.0 28.3
IVD past year 0.6 0.8 0 0.7 2.9 2.2 19.8 27.1 1.2 0.8
Ever IVD 3.0 8.3 0.5 2.1 31.3 66.0 42.3 57.9 10.8 21.0
Last injection heroin 0.8 2.6 0 0.2 8.2 20.5 22.5 30.9 3.2 4.5
Last injection cocaine 0.3 1.7 0 0.5 6.6 18.4 12.4 22.8 2.6 5.5
Past month worry about food 15.3 14.0 14.3 19.2 23.8 22.3 40.6 39.5 27.2 22.6
Ever homeless 19.6 26.6 20.1 27.2 61.0 62.7 83.1 77.6 45.3 35.1
Homelessness, past month 2.9 2.3 2.4 3 11.7 3.7 40.0 22.1 6.4 2.7
Concurrent substance use, mental health, and treatment (%)
Ever smoked 58.5 56.1 68.3 69.5 85.0 90.6 89.1 91.4 79.2 76.4
Smokes currently 25.4 28.4 31.5 38.7 53.7 55.5 77.1 81.6 51.5 49.5
Alcohol use* 61.3 58.6 74.6 74.6 46.3 38.9 83.9 80.8 79.2 84.0
AUDIT-C score, median (IQR) 1 (3) 1 (3) 2 (3) 2 (2) 2 (4) 2 (4) 3 (6) 3 (5) 3 (4) 2 (3)
Substance abuse treatment* 3.0 3.6 2.9 2.3 19.6 15.5 60.0 39.2 3.5 0.4
Methadone maintenance treatment* 0.3 1.1 0% 0.2 5.1 6.6 20.8 11.6 0.3 0
Psychiatric disease cluster 17.6 13.6 17.9 14.3 36.3 30.3 46.6 34.8 25.1 19.3
Schizophrenia 5.0 2.6 4.1 1.2 7.9 6.1 10.1 6.7 5.3 1.7
Major depression, bipolar 9.9 11.1 9.9 11.7 22.7 18.3 35.2 27.1 16.7 14.8
Post traumatic stress disorder 8.2 4.3 7.7 3.8 17.9 12.7 21.0 11.0 11.4 4.5
SF-12 Mental composite, median (IQR) 53.6 (15.3) 52.1 (15.5) 55.3 (14.5) 51.5 (17.7) 47.5 (20.2) 48.6 (16.7) 41.5 (18.8) 43.6 (18.0) 48.8 (18.9) 45.9 (18.7)
Mental health treatment* 21.4 19.1 22.8 19.9 45.0 33.8 73.2 45.6 29.5 21.0
Physical and medical conditions (%)
BMI categories Obese 42.0 15.7 41.0 11.3 43.5 20.1 32.0 9.4 37.7 8.8
Overweight†‡ 37.5 38.0 41.2 42.0 33.3 37.1 37.8 33.8 36.0 34.9
Underweight†‡ 1.2 4.2 1.2 2.8 0.9 2.6 1.9 4.1 1.5 5.1
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prevalences reported for class 1 and 2. For the HIV uninfected,
socio-demographics (e.g., employment, history of homelessness,
educational status) and high AUDIT-C scores were more akin to
those of multidrug users (class 3, 4). Past year alcohol use was
reported by approximately 80% of this class and, generally, mem-
bers were less likely to have been treated recently for substance
abuse.
Regarding health status, the HIV-infected in class 5 had the low-
est prevalence of obesity and a (non significant) high prevalence
of being underweight. In contrast, prevalence of obesity was sim-
ilar among the HIV uninfected in this class to those not currently
using drugs. The HIV uninfected had lower physical than mental
quality of life composite scores. Regardless of HIV status, class 5
exhibited poor quality of life on the SF-12 mental composite akin
to currentmultidrug users yet unlike them receipt ofmental health
treatment was low. Medical and psychiatric disease prevalence in
the HIV uninfected fell between those of classes 1, 2 and of 3, 4. A
lower prevalence of AIDS-associated illness and medical and psy-
chiatric diseasewas associatedwith this class’sHIV-infected, in line
with or lower than classes of users without a history of multidrug
use.
Taken together, the Tables 2 and 3 data suggested that, more
than a year ago, some of class 5 members transitioned away from
hard drug use (i.e., HIV−, HIV+: 0.16, 0.21 probability of past
heroin/opioid, 0.32, 0.43 past cocaine/stimulant) and injecting (i.e.,
1.2%, 0.8% current injecting, 10.8%, 21.0% history of injecting) to pri-
marily marijuana use. Other responses (e.g., never use) suggested
initiation or continued use of primarily marijuana.
4. Discussion
This study used LCA to discover subpopulations of drug users
and latent class regression to explicitly incorporate the influence
of HIV status on their composition. We observed considerable drug
use among an older adult population, one which is often not recog-
nized asHIV-infectedordrugusing (Bhavanet al., 2008; Effros et al.,
2008; Goulet et al., 2007; Hartel et al., 2006). A table in the online
Appendix A1 summarizes the findings including similarities among
classes, distinguishing characteristics, and HIV-specific results.
The continued drug use and specific patterns detected in our
sample extend findings reported from other studies of aging, drug
use, andHIV (Hartel et al., 2006; Hser et al., 2001; Lieberman, 2000;
Pitts et al., 2005; Rosenberg, 1995; Schlaerth, 2007; Schlaerth et al.,
2004). Similarities in drug use of HIV-infected and uninfected pop-
ulations exist, suggesting that the general medicine clinic controls
match well to the HIV-infected. However, key differences by HIV
status emerged from this analysis, with clinical and public health
implications for HIV and aging populations.
We found that drug use and abuse were lower but not uncom-
mon among those of older ages, with illness, or even with HIV.
These findings reinforce the need for age-appropriate treatment
and harm reduction services and for physicians and caregivers to
continue screening for substanceabuseanddependence, regardless
of their patient’s age or disease status. Health maintenance guide-
lines for geriatric care (e.g., http://www.americangeriatrics.org)
and for people aging with HIV make limited mention of substance
abuse screening (Bhavan et al., 2008).
Within the HIV-infected and uninfected in the VACS, psychi-
atric comorbidities,medical comorbidities, and their co-occurrence
were more prevalent in people with current and past histories of
multidrug use but were far less prevalent among current primarily
marijuana users. The “multimorbidity” among Veterans with HIV
1 Appendix – A summary of results is available as a table with the online version
of this article at doi:10.1016/j.drugalcdep.2010.02.020.
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Table 4
Variables independently associated with class membership, latent class analysis with covariates results stratified by HIV status (reference =Class 1, non-users).
Past, primarily marijuana
Class 2
Past multidrug
Class 3
High consequence, multidrug
Class 4
Low consequence, primarily marijuana
Class 5
HIV− HIV+ HIV− HIV+ HIV− HIV+ HIV− HIV+
Age (ref = 41–50) <40 1.14 0.74 0.41 0.28 0.49 0.54 1.45 0.76
(0.78, 1.65) (0.49, 1.11) (0.24, 0.70) (0.14, 0.54) (0.29, 0.85) (0.32, 0.90) (0.72, 1.81) (0.52, 1.12)
51–60 0.76 1.07 0.60 0.85 0.31 0.60 0.79 0.82
(0.55, 1.04) (0.75, 1.53) (0.44, 0.82) (0.59, 1.21) (0.19, 0.50) (0.40, 0.90) (0.55, 1.13) (0.58, 1.15)
>60 0.29 0.38 0.18 0.33 0.11 0.25 0.36 0.21
(0.18, 0.45) (0.24, 0.61) (0.11, 0.30) (0.18, 0.59) (0.03, 0.37) (0.12, 0.51) (0.21, 0.61) (0.12, 0.36)
African American 1.11 0.53 1.30 1.13 2.90 3.06 1.09 0.63
(0.83, 1.49) (0.38, 0.74) (0.94, 1.80) (0.73, 1.76) (1.62, 5.19) (1.59, 5.90) (0.77, 1.54) (0.45, 0.88)
Hispanic/other 1.00 0.59 1.20 1.36 1.22 1.91 0.87 0.83
(0.66, 1.50) (0.36, 0.97) (0.78, 1.85) (0.78, 2.36) (0.57, 2.63) (0.91, 4.03) (0.54, 1.40) (0.52, 1.34)
Currently employed 0.82 0.98 0.98 0.85 0.51 0.47 0.60 0.72
(0.62, 1.08) (0.71, 1.34) (0.70, 1.31) (0.59, 1.21) (0.33, 0.79) (0.32, 0.71) (0.44, 0.83) (0.52, 0.99)
Alcohol use past year 1.51 2.06 0.52 0.52 3.16 2.99 1.87 3.65
(1.10, 2.06) (1.44, 2.96) (0.37, 0.73) (0.35, 0.77) (1.86, 5.39) (1.91, 4.70) (1.30, 2.70) (2.55, 5.22)
AUDIT-C score 1.04 1.03 1.13 1.18 1.16 1.20 1.13 1.08
(0.97, 1.11) (0.95, 1.12) (1.06, 1.20) (1.09, 1.27) (1.07, 1.25) (1.10, 1.30) (1.06, 1.21) (1.01, 1.15)
Ever smoked 1.92 1.93 2.56 2.85 1.66 1.57 1.92 2.13
(1.39, 2.66) (1.34, 2.79) (1.73, 3.80) (1.78, 4.57) (0.90, 3.07) (0.84, 2.94) (1.29, 2.86) (1.46, 3.10)
Smokes currently 0.84 1.00 1.12 1.59 1.82 3.57 1.45 1.27
(0.61, 1.16) (0.69, 1.44) (0.82, 1.53) (1.08, 2.33) (1.10, 2.99) (2.20, 5.81) (1.01, 2.07) (0.88, 1.82)
Ever homeless 1.18 (0.80,1.72) 0.89 2.96 2.21 4.22 3.36 2.58 1.11
(0.61, 1.28) (2.19, 4.01) (1.56, 3.11) (2.66, 6.71) (2.02, 5.61) (1.84, 3.65) (0.81, 1.52)
Past mo homeless 0.81 1.48 1.29 0.78 2.86 2.81 0.65 1.03
(0.36, 1.81) (0.57, 3.89) (0.74, 2.23) (0.33, 1.85) (1.58, 5.17) (1.27, 6.21) (0.31, 1.35) (0.37, 2.85)
Past mo worry about food 0.87 1.49 0.89a 1.17 1.32 1.82 1.16 1.38
(0.58, 1.31) (1.00, 2.22) (0.61, 1.32) (0.78, 1.75) (0.85, 2.06) (1.19, 2.78) (0.80, 1.68) (0.94, 2.03)
IVD past yr 0.30 1.46 1.37 0.59 7.67 12.26 1.40 0.53
(0.002, 47.42) (0.31, 6.76) (0.51, 3.70) (0.16, 2.10) (2.96, 19.84) (3.68, 40.87) (0.36, 5.42) (0.11, 2.51)
Ever IVD 0.16 0.39 7.61 11.61 9.43 7.29 2.72 2.94
(0.02, 1.33) (0.14, 1.05) (4.57, 12.65) (7.66, 17.59) (4.99, 17.80) (4.35, 12.24) (1.50, 4.93) (1.88, 4.57)
SF-12 mental composite score 1.01 1.00 0.99 0.99 0.97 0.99 0.99 0.98
(0.99, 1.02) (0.99, 1.02) (0.98, 1.00) (0.97, 1.01) (0.96, 0.99) (0.97, 1.00) (0.97, 1.00) (0.97, 0.99)
Past year SA treatment 1.14 (0.52, 2.47) 0.66 (0.21, 2.11) 3.75 (2.23, 6.30) 2.18 (1.12, 4.23) 17.91 (9.91, 32.39) 5.55 (2.80, 11.00) 0.98 (0.39, 2.46) 0.18 (0.04, 0.92)
BMI (ref =normal) Obese – 0.70 – 1.54 – 0.63 – 0.47
(0.45, 1.11) (0.98, 2.41) (0.38, 1.05) (0.30, 0.74)
Overweight – 1.12 – 1.07 – 0.78 – 0.81
(0.83, 1.52) (0.75, 1.52) (0.54, 1.15) (0.60, 1.09)
Underweight – 0.62 – 0.68 – 0.57 – 0.90
(0.27, 1.41) (0.31, 1.53) (0.21, 1.61) (0.42, 1.93)
Married – 0.83 – 0.77 – 0.48 – 1.04
(0.59, 1.15) (0.53, 1.13) (0.31, 0.75) (0.76, 1.43)
Sex (1 = female) 0.64 – 0.55 – 0.18 – 0.37 –
(0.41, 1.00) (0.34, 0.91) (0.07, 0.46) (0.20, 0.68)
Adjusted odds ratios and (95% confidence intervals). Reference class = non-users, Class 1.
Model is adjusted for all other significant covariates detected in multinomial regressions using the unadjusted LCA class results.
– = no estimate because variable not included in model.
SA = substance abuse, including alcohol and/or drug abuse, BMI = body mass index, IVD= intravenous drug use, AUDIT-C = alcohol use disorders identification test-consumption, SF-12 = short form 12.
Bold values are statistically significant from the reference non-user class within HIV status.
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and substance use disorder has been described previously (Goulet
et al., 2007). Our results expand upon this work by highlighting
the heterogeneity and range of multimorbidity by pattern of drug
use. This study did not capture severity of comorbidities, how-
ever, for similarprevalencesofmedical andpsychiatric comorbidity
diagnoses, members of the current multidrug users class reported
the lowest physical and mental quality of life scores. In addition,
AIDS-associated illness was highest in the current multidrug users
class. Results suggest that effectively treating the older adult HIV-
infected patient in the VA, as elsewhere, will entail addressing
multimorbidities as well as employing special efforts such as inter-
ventions to improve medication adherence and reduce depressive
symptoms (Altice et al., 2007, 2004; Safren et al., 2009), to keep
AIDS-associated illness at bay in older adults who continue mul-
tidrug use.
The low consequence, primarily marijuana users appear to be a
unique drug-using group. The low prevalence of drug dependence
and the absence of negative consequences despite chronic use runs
counter to research on cannabis abuse/dependence and their sub-
types (Grant et al., 2006). However, other LCA studies havedetected
the existenceof amarijuana-onlydruguse class amongst nationally
representative samples of lifetimedrug users (Agrawal et al., 2007).
Motivations for primarilymarijuanausemaybe amixture of transi-
tions away from use of other drugs, (re)initiation, self-medication,
or evidence of diffusion of medical marijuana as innovative treat-
ment (e.g., appetite stimulation, management of medication side
effects (de Jong et al., 2005; Haney et al., 2007; Kuo et al., 2004)),
which might be better known to the HIV community and their
physicians. Whether this class represents a later stage of drug use,
as suggested by similarities to the multidrug user classes for the
HIV uninfected, a therapeutic disease-specific class, as suggested
by similarities to the non-user and past marijuana users for the
HIV-infected, or if differences indicate two separate pathways into
this class, is open for inquiry.
The discovered classes appear to be valid, as indicated by the
association between the clinical diagnostic criteria in the expected
directions and by the covariates predictive of class membership.
For example, one would have expected, as was found, that recent
injecting drug use would be strongly related to the high con-
sequence, multidrug users (class 4) but not to any other class.
Adjusting for covariates improved our models’ fit, aligning results
closer to the true class membership and highlighting the inter-
play of predisposing (e.g., race, gender, homelessness), enabling
(e.g., income, education), and need (e.g., comorbidities) factors
expected under Gelberg’s Behavioral Model for Vulnerable Popu-
lations (Gelberg et al., 2000). Other reported LCAs of drug abuse
(e.g., (Agrawal et al., 2007; Monga et al., 2007) have not adjusted
for covariates.
Some of our findings concur with previously reported LCAs,
which detected classes of marijuana-only and multidrug users
(Agrawal et al., 2007), while there are also some classes we could
not detect, such as prescription drug abusers. Differences may be
explained by choice of study sample (age, illness status), expo-
sure assessment (lifetime versus past year use, types of drugs
assessed), choice of model (dichotomous, ordinal, etc.), and inclu-
sion of covariates, among others.
Future studies should explore longitudinal transitions between
classes and test hypotheses about class membership. Little is
known about how frequently older HIV-infected and uninfected
drug users move in and out of treatment, initiate and terminate
drug use, and switch to other substances (Hser et al., 2007). It
has been hypothesized that the increasing isolation experienced
as one ages may promote transitions from “harder” drugs (e.g.,
heroin) which may be used alone to “softer” drugs (e.g., marijuana)
used more socially (Fogarty et al., 2007; Osborne and Fogel, 2008;
Schlaerth et al., 2004). Future endeavors should also test the utility
and validity of our derived drug use classes in predicting key health
outcomes.
This study has several limitations. The crucial limitation is its
cross-sectional nature. One cannot conclude from our data, for
example, that drug use decreases with increasing age but rather
that, at the ages represented in VACS, probability of certain class
membership is lower at older ages. In cross-sectional designs, it
is also not possible to determine whether the classes of current
and past drug users are stable or dynamic, whether they represent
switching of substances or harm minimizing use, intensification
or diminution of particular substances used over time, or whether
members are incident, chronic prevalent or relapse case members.
Longitudinal analyses are underway to address such questions. In
the meantime, this study presents hypothesis-generating, initial
descriptions and comparisons by HIV status of an aging, consider-
ably active drug-using population. Also, VACS focuses on an aging
population, thus our studymaynot be representative of youngHIV-
infected Veterans and women, who could have different drug use
patterns. The largely male older Veteran population of the VACS
may also not be representative of aging adults more generally.
However, drug use in older adults occurs predominantly among
males (Armstrong, 2007; Han et al., 2009a; Zanjani et al., 2007)
and the high degree of drug use found in the VACS HIV uninfected
population shares similarities with use among older people in the
general population described by others (Han et al., 2009b). Preva-
lence of club drug and benzodiazepine use was not assessed, hence
we may have underestimated the true prevalence of drug use. Pre-
scription opioid abusewas notmeasured separately fromheroin so
any potential transition to these substances would not be detected
in item-responseprobabilities. Finally, theextent towhichourfind-
ings generalize to non-Veterans is unknown. While Veterans in
care generally differ substantially from theUS population receiving
health care, Veterans in care with HIV infection have much in com-
mon with others receiving treatment for HIV infection (Conigliaro
et al., 2006; Kohli et al., 2005; Lohse et al., 2007; Palella et al., 2006).
As evidence of this fact, VACS data was directly compared to other
large HIV cohorts in Europe and North America and deemed con-
sistent enough with these other samples to be combined in two
high profile cross cohort analyses (Kitahata et al., 2009; Sterne et
al., 2009).
The prevalence of any current drug use (classes 4 and 5) in
the VACS was 44.5% among HIV-infected and 30% among HIV
uninfected. Relying on clinical reports of drug dependence would
insteadplace theestimateat25% (ICD-9code)or14% (CIDI-SF),with
no statistical differences by HIV status. Moreover, there was sub-
stantial divergence between EMR and self-reported data (CIDI-SF
or LCA) for the pastmultidrug user class, implyingmisclassification
of past users as current users in the EMR. An LCA approach to expo-
sure measurement serves as a descriptive and analytic tool to find
consensus in patterns of behavior reported by participants in away
that incorporates rather than punishes for measurement error and
missing data typical in observational study. As the application of
LCA continues to expand (Muthen, 1992, 2008), our study suggests
that LCA can be used to detect statistically and clinically valid sub-
populations of drug users without having to administer lengthy
interviews or having to rely solely on medical record-generated
proxies of drug abuse/dependence.
Our findings contribute to the increasing literature on drug use,
aging, and HIV (Bhavan et al., 2008; Effros et al., 2008; Ettenhofer
et al., 2009; Han et al., 2009a,b) and are directly relevant to
the VA, which provides treatment and care to more than 19,000
people with HIV and 213,000 people diagnosed with Substance
Abuse Disorders as well as to Veterans with undetected diagnoses.
Specifically, intervention should be prioritized for the problematic
multidrug user class, who showed considerable need, poor health,
and low quality of life. Results lend support for efforts to inte-
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gratemental health, chronic disease, andHIV care; implementation
of screening for improved detection of drug abuse and poten-
tial referral for specialized care; and expansion of age-appropriate
treatment and harm reduction options for drug users.
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